News

Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces

Ares Commercial Real Estate (ACRE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most

Freightos Limited (CRGO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces

Investors might want to bet on Wolters Kluwer NV (WTKWY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates

Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates

Midland States Bancorp (MSBI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates

Investors might want to bet on Global-e Online Ltd. (GLBE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is

Eastern Bankshares, Inc. (EBC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces

Clearside Biomedical, Inc. (CLSD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell

The stock market has been one heck of a seesaw in 2025.

A bit over a month ago, the S&P 500 was down more than 15% on the year and narrowly avoided an official bear market (in fact, it closed down

Fortinet FTNT shares have gained 10.6% in the year-to-date (YTD) period, outperforming the Zacks Computer and Technology sector and the S&P 500 index’s decline of 1.7% and 0.4%, respectively.FTNT’s

Both Spotify Technology S.A. SPOT and UiPath PATH are prominent software-driven tech stocks. SPOT is a leading personalized audio streaming and content platform, while PATH focuses on robotic

Shares of ORIC Pharmaceuticals ORIC surged more than 20% in the pre-market hours today after announcing potentially best-in-class preliminary efficacy and safety data from the ongoing early-stage

An updated edition of the April 08, 2025 article.

3D Printing, or additive manufacturing, is the process of transforming digital designs into physical objects by building them layer by layer with

Okta OKTA shares dropped 16.16% on Wednesday to close at $105.22 following first-quarter fiscal 2026 results on Tuesday. Although the company reported impressive earnings and revenue growth, the

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The decision applies to all 27